Amgen Licenses Astellas-Partnered AMG 337 To NantPharma
This article was originally published in Scrip
NantPharma LLC, a subsidiary of Patrick Soon-Shiong's NantWorks LLC empire, licensed AMG 337 outside of Japan, Russia and other central Asian countries from Amgen Inc., which previously partnered with Astellas Pharma Inc. to develop the cancer drug and four other compounds in certain Asia territories.
You may also be interested in...
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.